{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:11:57Z","timestamp":1789330317111,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA226921"],"award-info":[{"award-number":["R01CA226921"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic breast cancer is responsible for the death of the majority of breast cancer patients. In fact, metastatic BC is the 2nd leading cause of cancer-related deaths in women in the USA and worldwide. Triple negative breast cancer (TNBC), which lacks expression of hormone receptors (ER-\u03b1 and PR) and ErbB2\/HER2, is especially lethal due to its highly metastatic behavior, propensity to recur rapidly, and for its resistance to standard of care therapies, through mechanisms that remain incompletely understood. WAVE3 has been established as a promoter of TNBC development and metastatic progression. In this study, we investigated the molecular mechanisms whereby WAVE3 promotes therapy-resistance and cancer stemness in TNBC, through the regulation of \u03b2-catenin stabilization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Cancer Genome Atlas dataset was used to assess the expression of WAVE3 and \u03b2-catenin in breast cancer tumors. Kaplan\u2013Meier Plotter analysis was used to correlate expression of WAVE3 and \u03b2-catenin with breast cancer patients\u2019 survival probability. MTT assay was used to quantify cell survival. CRISPR\/Cas9-mediated gene editing, 2D and 3D tumorsphere growth and invasion assays, Immunofluorescence, Western blotting, Semi-quantitative and real-time quantitative PCR analyses were applied to study the WAVE3\/\u03b2-catenin oncogenic signaling in TNBC. Tumor xenograft assays were used to study the role of WAVE3 in mediating chemotherapy resistance of TNBC tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Genetic inactivation of WAVE3 in combination of chemotherapy resulted in inhibition of 2D growth and 3D tumorsphere formation and invasion of TNBC cells in vitro, as well as tumor growth and metastasis in vivo. In addition, while re-expression of phospho-active WAVE3 in the WAVE3-deficient TNBC cells restored the oncogenic activity of WAVE3, re-expression of phospho-mutant WAVE3 did not. Further studies revealed that dual blocking of WAVE3 expression or phosphorylation in combination with chemotherapy treatment inhibited the activity and expression and stabilization of \u03b2-catenin. Most importantly, the combination of WAVE3-deficiency or WAVE3-phospho-deficiency and chemotherapy suppressed the oncogenic behavior of chemoresistant TNBC cells, both in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We identified a novel WAVE3\/\u03b2-catenin oncogenic signaling axis that modulates chemoresistance of TNBC. This study suggests that a targeted therapeutic strategy against WAVE3 could be effective for the treatment of chemoresistant TNBC tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-023-01634-3","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T10:09:02Z","timestamp":1679479742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The WAVE3\/\u03b2-catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka S.","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Sossey-Alaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"1634_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1634_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature"},{"key":"1634_CR3","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1634_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4137\/CIN.S9983","volume":"11","author":"X Chen","year":"2012","unstructured":"Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, et al. TNBCtype: a subtyping tool for triple-negative breast Cancer. Cancer Inform. 2012;11:147\u201356.","journal-title":"Cancer Inform"},{"key":"1634_CR5","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"1634_CR6","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348.","journal-title":"N Engl J Med"},{"key":"1634_CR7","doi-asserted-by":"publisher","first-page":"8010","DOI":"10.1158\/1078-0432.CCR-08-1208","volume":"14","author":"BP Schneider","year":"2008","unstructured":"Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14:8010\u20138.","journal-title":"Clin Cancer Res"},{"key":"1634_CR8","first-page":"287","volume":"24","author":"K Sossey-Alaoui","year":"2013","unstructured":"Sossey-Alaoui K. Surfing the big WAVE: Insights into the role of WAVE3 as a driving force in cancer progression and metastasis. Semin Cell Dev Biol. 2013;24:287\u201397.","journal-title":"Semin Cell Dev Biol"},{"key":"1634_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020836","author":"R Loveless","year":"2021","unstructured":"Loveless R, Teng Y. Targeting WASF3 signaling in metastatic cancer. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22020836.","journal-title":"Int J Mol Sci"},{"key":"1634_CR10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.21037\/atm.2020.02.16","volume":"8","author":"U Kansakar","year":"2020","unstructured":"Kansakar U, Wang W, Markovic V, Sossey-Alaoui K. Elucidating the molecular signaling pathways of WAVE3. Ann Transl Med. 2020;8:900.","journal-title":"Ann Transl Med"},{"key":"1634_CR11","doi-asserted-by":"publisher","first-page":"104072","DOI":"10.18632\/oncotarget.22009","volume":"8","author":"K Bledzka","year":"2017","unstructured":"Bledzka K, Schiemann B, Schiemann WP, Fox P, Plow EF, Sossey-Alaoui K. The WAVE3-YB1 interaction regulates cancer stem cells activity in breast cancer. Oncotarget. 2017;8:104072\u201389.","journal-title":"Oncotarget"},{"key":"1634_CR12","first-page":"e1009276","volume":"3","author":"G Davuluri","year":"2014","unstructured":"Davuluri G, Schiemann WP, Plow EF, Sossey-Alaoui K. Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1alpha-mediated angiogenesis. JAKSTAT. 2014;3:e1009276.","journal-title":"JAKSTAT"},{"key":"1634_CR13","doi-asserted-by":"publisher","first-page":"e110627","DOI":"10.1371\/journal.pone.0110627","volume":"9","author":"G Davuluri","year":"2014","unstructured":"Davuluri G, Augoff K, Schiemann WP, Plow EF, Sossey-Alaoui K. WAVE3-NFkappaB interplay is essential for the survival and invasion of cancer cells. PLoS ONE. 2014;9:e110627.","journal-title":"PLoS ONE"},{"key":"1634_CR14","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/s41598-021-83479-4","volume":"11","author":"U Kansakar","year":"2021","unstructured":"Kansakar U, Wang W, Markovic V, Sossey-Alaoui K. Phosphorylation of the proline-rich domain of WAVE3 drives its oncogenic activity in breast cancer. Sci Rep. 2021;11:3868.","journal-title":"Sci Rep"},{"key":"1634_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.gendis.2015.12.004","volume":"3","author":"MK Mohammed","year":"2016","unstructured":"Mohammed MK, Shao C, Wang J, Wei Q, Wang X, Collier Z, et al. Wnt\/beta-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis. 2016;3:11\u201340.","journal-title":"Genes Dis"},{"key":"1634_CR16","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.2217\/fon-2021-0172","volume":"17","author":"H Qayoom","year":"2021","unstructured":"Qayoom H, Wani NA, Alshehri B, Mir MA. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer. Future Oncol. 2021;17:4185\u2013206.","journal-title":"Future Oncol"},{"key":"1634_CR17","doi-asserted-by":"publisher","first-page":"26257","DOI":"10.1074\/jbc.M701484200","volume":"282","author":"K Sossey-Alaoui","year":"2007","unstructured":"Sossey-Alaoui K, Li X, Cowell JK. c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration. J Biol Chem. 2007;282:26257\u201365.","journal-title":"J Biol Chem"},{"key":"1634_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41389-020-00272-0","volume":"9","author":"W Wang","year":"2020","unstructured":"Wang W, Kansakar U, Markovic V, Wang B, Sossey-Alaoui K. WAVE3 phosphorylation regulates the interplay between PI3K, TGF-beta, and EGF signaling pathways in breast cancer. Oncogenesis. 2020;9:87.","journal-title":"Oncogenesis"},{"key":"1634_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13246262","author":"PS Rana","year":"2021","unstructured":"Rana PS, Wang W, Alkrekshi A, Markovic V, Khiyami A, Chan R, et al. YB1 is a major contributor to health disparities in triple negative breast cancer. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13246262.","journal-title":"Cancers (Basel)"},{"key":"1634_CR20","doi-asserted-by":"publisher","first-page":"e42895","DOI":"10.1371\/journal.pone.0042895","volume":"7","author":"S Kulkarni","year":"2012","unstructured":"Kulkarni S, Augoff K, Rivera L, McCue B, Khoury T, Groman A, et al. Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer. PLoS ONE. 2012;7:e42895.","journal-title":"PLoS ONE"},{"key":"1634_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12935-021-02107-3","volume":"21","author":"P Merikhian","year":"2021","unstructured":"Merikhian P, Eisavand MR, Farahmand L. Triple-negative breast cancer: understanding Wnt signaling in drug resistance. Cancer Cell Int. 2021;21:419.","journal-title":"Cancer Cell Int"},{"key":"1634_CR22","doi-asserted-by":"publisher","first-page":"33019","DOI":"10.1074\/jbc.M109.034553","volume":"284","author":"K Sossey-Alaoui","year":"2009","unstructured":"Sossey-Alaoui K, Bialkowska K, Plow EF. The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J Biol Chem. 2009;284:33019\u201329.","journal-title":"J Biol Chem"},{"key":"1634_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10549-013-2753-1","volume":"142","author":"MA Taylor","year":"2013","unstructured":"Taylor MA, Davuluri G, Parvani JG, Schiemann BJ, Wendt MK, Plow EF, et al. Upregulated WAVE3 expression is essential for TGF-beta-mediated EMT and metastasis of triple-negative breast cancer cells. Breast Cancer Res Treat. 2013;142:341\u201353.","journal-title":"Breast Cancer Res Treat"},{"key":"1634_CR24","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1038\/s41388-020-1382-5","volume":"39","author":"D Braggio","year":"2020","unstructured":"Braggio D, Zewdu A, Londhe P, Yu P, Lopez G, Batte K, et al. beta-catenin S45F mutation results in apoptotic resistance. Oncogene. 2020;39:5589\u2013600.","journal-title":"Oncogene"},{"key":"1634_CR25","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1038\/onc.2009.80","volume":"28","author":"M Flahaut","year":"2009","unstructured":"Flahaut M, Meier R, Coulon A, Nardou KA, Niggli FK, Martinet D, et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt\/beta-catenin pathway. Oncogene. 2009;28:2245\u201356.","journal-title":"Oncogene"},{"key":"1634_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","volume":"62","author":"N Krishnamurthy","year":"2018","unstructured":"Krishnamurthy N, Kurzrock R. Targeting the Wnt\/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev. 2018;62:50\u201360.","journal-title":"Cancer Treat Rev"},{"key":"1634_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1476-4598-9-145","volume":"9","author":"YY Liu","year":"2010","unstructured":"Liu YY, Gupta V, Patwardhan GA, Bhinge K, Zhao Y, Bao J, et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer. 2010;9:145.","journal-title":"Mol Cancer"},{"key":"1634_CR28","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/0008-5472.CAN-20-2801","volume":"81","author":"HM Quinn","year":"2021","unstructured":"Quinn HM, Vogel R, Popp O, Mertins P, Lan L, Messerschmidt C, et al. YAP and beta-catenin cooperate to drive oncogenesis in basal breast cancer. Cancer Res. 2021;81:2116\u201327.","journal-title":"Cancer Res"},{"key":"1634_CR29","doi-asserted-by":"publisher","first-page":"7384","DOI":"10.7150\/thno.37892","volume":"9","author":"T Tang","year":"2019","unstructured":"Tang T, Guo C, Xia T, Zhang R, Zen K, Pan Y, et al. LncCCAT1 promotes breast cancer stem cell function through activating WNT\/beta-catenin signaling. Theranostics. 2019;9:7384\u2013402.","journal-title":"Theranostics"},{"key":"1634_CR30","doi-asserted-by":"publisher","first-page":"e0155983","DOI":"10.1371\/journal.pone.0155983","volume":"11","author":"HS Won","year":"2016","unstructured":"Won HS, Lee KM, Oh JE, Nam EM, Lee KE. Inhibition of beta-catenin to overcome endocrine resistance in tamoxifen-resistant breast cancer cell line. PLoS ONE. 2016;11:e0155983.","journal-title":"PLoS ONE"},{"key":"1634_CR31","doi-asserted-by":"publisher","first-page":"5854","DOI":"10.1038\/s41388-021-01986-0","volume":"40","author":"F Zhang","year":"2021","unstructured":"Zhang F, Li P, Liu S, Yang M, Zeng S, Deng J, et al. \u03b2-Catenin-CCL2 feedback loop mediates crosstalk between cancer cells and macrophages that regulates breast cancer stem cells. Oncogene. 2021;40:5854\u201365.","journal-title":"Oncogene"},{"key":"1634_CR32","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1038\/onc.2016.10","volume":"35","author":"ZM Zhang","year":"2016","unstructured":"Zhang ZM, Wu JF, Luo QC, Liu QF, Wu QW, Ye GD, et al. Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt\/beta-catenin pathway. Oncogene. 2016;35:4787\u201397.","journal-title":"Oncogene"},{"issue":"Suppl 2","key":"1634_CR33","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.3816\/CBC.2009.s.008","volume":"9","author":"CK Anders","year":"2009","unstructured":"Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9(Suppl 2):S73-81.","journal-title":"Clin Breast Cancer"},{"key":"1634_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030482","author":"EE Newton","year":"2022","unstructured":"Newton EE, Mueller LE, Treadwell SM, Morris CA, Machado HL. Molecular targets of triple-negative breast cancer: where do we stand? Cancers. 2022. https:\/\/doi.org\/10.3390\/cancers14030482.","journal-title":"Cancers"},{"key":"1634_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031665","author":"P Ferrari","year":"2022","unstructured":"Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A. Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23031665.","journal-title":"Int J Mol Sci"},{"key":"1634_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1006\/bbrc.1999.0894","volume":"260","author":"S Suetsugu","year":"1999","unstructured":"Suetsugu S, Miki H, Takenawa T. Identification of two human WAVE\/SCAR homologues as general actin regulatory molecules which associate with the Arp2\/3 complex. Biochem Biophys Res Commun. 1999;260:296\u2013302.","journal-title":"Biochem Biophys Res Commun"},{"key":"1634_CR37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1021\/acsmedchemlett.1c00627","volume":"13","author":"AJ Limaye","year":"2022","unstructured":"Limaye AJ, Bendzunas GN, Whittaker MK, LeClair TJ, Helton LG, Kennedy EJ. In silico optimized stapled peptides targeting WASF3 in breast cancer. ACS Med Chem Lett. 2022;13:570\u20136.","journal-title":"ACS Med Chem Lett"},{"key":"1634_CR38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13046-021-02083-6","volume":"40","author":"Y Teng","year":"2021","unstructured":"Teng Y, Loveless R, Benson EM, Sun L, Shull AY, Shay C. SHOX2 cooperates with STAT3 to promote breast cancer metastasis through the transcriptional activation of WASF3. J Exp Clin Cancer Res. 2021;40:274.","journal-title":"J Exp Clin Cancer Res"},{"key":"1634_CR39","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/cas.14423","volume":"111","author":"N Shibuya","year":"2020","unstructured":"Shibuya N, Kakeji Y, Shimono Y. MicroRNA-93 targets WASF3 and functions as a metastasis suppressor in breast cancer. Cancer Sci. 2020;111:2093\u2013103.","journal-title":"Cancer Sci"},{"key":"1634_CR40","doi-asserted-by":"publisher","first-page":"1874387","DOI":"10.1155\/2020\/1874387","volume":"2020","author":"XJ Gou","year":"2020","unstructured":"Gou XJ, Bai HH, Liu LW, Chen HY, Shi Q, Chang LS, et al. Asiatic acid interferes with invasion and proliferation of breast cancer cells by inhibiting WAVE3 activation through PI3K\/AKT signaling pathway. Biomed Res Int. 2020;2020:1874387.","journal-title":"Biomed Res Int"},{"key":"1634_CR41","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/0008-5472.CAN-15-1680","volume":"76","author":"Y Teng","year":"2016","unstructured":"Teng Y, Bahassan A, Dong D, Hanold LE, Ren X, Kennedy EJ, et al. Targeting the WASF3-CYFIP1 complex using stapled peptides suppresses cancer cell invasion. Cancer Res. 2016;76:965\u201373.","journal-title":"Cancer Res"},{"key":"1634_CR42","first-page":"e28086","volume":"3","author":"Y Teng","year":"2014","unstructured":"Teng Y, Ross JL, Cowell JK. The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. JAKSTAT. 2014;3:e28086.","journal-title":"JAKSTAT"},{"key":"1634_CR43","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-020-01276-5","volume":"19","author":"X Xu","year":"2020","unstructured":"Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020;19:165.","journal-title":"Mol Cancer"},{"key":"1634_CR44","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.1038\/onc.2010.365","volume":"29","author":"J Dhillon","year":"2010","unstructured":"Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene. 2010;29:6294\u2013300.","journal-title":"Oncogene"},{"key":"1634_CR45","doi-asserted-by":"publisher","first-page":"8837","DOI":"10.1158\/1078-0432.CCR-05-0945","volume":"11","author":"T Fujita","year":"2005","unstructured":"Fujita T, Ito K, Izumi H, Kimura M, Sano M, Nakagomi H, et al. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res. 2005;11:8837\u201344.","journal-title":"Clin Cancer Res"},{"key":"1634_CR46","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/j.biocel.2008.04.011","volume":"40","author":"D Guay","year":"2008","unstructured":"Guay D, Evoy AA, Paquet E, Garand C, Bachvarova M, Bachvarov D, et al. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures. Int J Biochem Cell Biol. 2008;40:2492\u2013507.","journal-title":"Int J Biochem Cell Biol"},{"key":"1634_CR47","doi-asserted-by":"publisher","first-page":"R86","DOI":"10.1186\/bcr2156","volume":"10","author":"G Habibi","year":"2008","unstructured":"Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008;10:R86.","journal-title":"Breast Cancer Res"},{"key":"1634_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-011-1731-8","volume":"133","author":"T Ito","year":"2012","unstructured":"Ito T, Kamijo S, Izumi H, Kohno K, Amano J, Ito K. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2012;133:145\u201359.","journal-title":"Breast Cancer Res Treat"},{"key":"1634_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ijc.1610","volume":"97","author":"M Janz","year":"2002","unstructured":"Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer. 2002;97:278\u201382.","journal-title":"Int J Cancer"},{"key":"1634_CR50","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1038\/sj.onc.1208590","volume":"24","author":"BW Sutherland","year":"2005","unstructured":"Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 2005;24:4281\u201392.","journal-title":"Oncogene"},{"key":"1634_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102795","author":"A Tiwari","year":"2020","unstructured":"Tiwari A, Iida M, Kosnopfel C, Abbariki M, Menegakis A, Fehrenbacher B, et al. Blocking Y-box binding protein-1 through simultaneous targeting of PI3K and MAPK in triple negative breast cancers. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12102795.","journal-title":"Cancers"},{"key":"1634_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10555-008-9179-y","volume":"28","author":"O Schmalhofer","year":"2009","unstructured":"Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151\u201366.","journal-title":"Cancer Metastasis Rev"},{"key":"1634_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/onc.2012.565","volume":"33","author":"Y Teng","year":"2014","unstructured":"Teng Y, Mei Y, Hawthorn L, Cowell JK. WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells. Oncogene. 2014;33:203\u201311.","journal-title":"Oncogene"},{"key":"1634_CR54","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.canlet.2019.03.014","volume":"452","author":"JP Lim","year":"2019","unstructured":"Lim JP, Nair S, Shyamasundar S, Chua PJ, Muniasamy U, Matsumoto K, et al. Silencing Y-box binding protein-1 inhibits triple-negative breast cancer cell invasiveness via regulation of MMP1 and beta-catenin expression. Cancer Lett. 2019;452:119\u201331.","journal-title":"Cancer Lett"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-023-01634-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-023-01634-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-023-01634-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T10:18:01Z","timestamp":1679480281000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-023-01634-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1186\/s13058-023-01634-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2042135\/v1","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"assertion":[{"value":"7 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were performed under protocols approved by the Institutional Animal Care and Use Committee at Case Western Reserve University and MetroHealth System.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}